Capsugel (now Lonza) Strategic Review: What B2B Partners Need to Know

France — 31 July 2026

Capsugel, now an integral part of Lonza's Pharma & Biotech division, represents a foundational element of the global supplement industry. While often operating behind the scenes, their expertise in dosage form solutions, particularly capsule technology, dictates market trends in bioavailability, consumer preference, and product differentiation. Their influence extends beyond mere encapsulation, shaping how novel ingredients reach the consumer effectively and safely.

Company Snapshot

Lonza, headquartered in Basel, Switzerland, is a global manufacturing partner to the pharma, biotech, and nutrition industries. Key product lines from the Capsugel legacy include Vcaps® vegetarian capsules, Licaps® liquid-filled hard capsules, and a range of specialised dosage forms designed for targeted release and enhanced absorption. They operate across multiple countries with a substantial global workforce.

Strategic Position and Recent Moves

Lonza's strategy for its Capsugel assets continues to focus on high-value, differentiated dosage forms and integrated solutions. Recent announcements have included significant expansion of capsule manufacturing capacity in Greenwood, South Carolina, with substantial investment aimed at meeting rising demand for vegetarian and clean-label encapsulation. This move directly addresses the increasing consumer preference for plant-based solutions. Furthermore, Lonza has been actively pursuing strategic partnerships to broaden its offering. They have formalised collaborations to develop novel capsule technologies specifically tailored for probiotic delivery, a market segment experiencing substantial growth. These initiatives follow acquisitions of specialised ingredient firms to enhance formulation expertise in complex lipid-based ingredients. Lonza's moves reflect a clear understanding that the future of supplements isn't just about the active ingredient, but how effectively it's delivered and perceived by the consumer. Their investment in vegetarian capsules and targeted delivery systems positions them strongly in premium segments against competitors like ACG.

What Manufacturers Can Learn

Capsugel (Lonza)'s strategic trajectory provides critical insights for contract manufacturers and ingredient suppliers. The emphasis on vegetarian and clean-label capsules underscores the enduring consumer demand for transparency and plant-based options; any manufacturer not offering these solutions is increasingly at a disadvantage. Their focus on advanced delivery systems, such as liquid-filled hard capsules and enteric-coated options, highlights the growing importance of bioavailability and targeted release in product efficacy. This signals that mere ingredient supply is insufficient; suppliers must consider how their ingredients perform within sophisticated delivery matrices. Manufacturers should also note the trend towards integrated solutions, where the capsule provider offers formulation expertise alongside encapsulation. This suggests a move away from siloed operations towards more collaborative, end-to-end development partnerships.

Risks and Headwinds

Despite its strong market position, Capsugel (Lonza) faces several challenges. Regulatory scrutiny around novel excipients and processing aids is intensifying, requiring continuous investment in compliance and R&D. The competitive landscape remains robust, with players like ACG, Qualicaps, and HealthCaps International constantly innovating and vying for market share, particularly in cost-sensitive segments. Furthermore, the broader economic climate and supply chain volatility could impact raw material costs and lead times, potentially affecting profitability and customer commitments. There's also the perennial risk of intellectual property infringement, particularly in rapidly evolving capsule technologies. While Lonza's scale offers advantages, the pace of innovation in delivery systems means they cannot rest on their laurels. Smaller, agile competitors can sometimes outmanoeuvre larger players on niche applications or speed to market.

The B2B Verdict

Supplement businesses should absolutely be watching Capsugel (Lonza) closely. Their investments and strategic direction are bellwethers for the broader industry, especially concerning delivery technology and consumer-driven trends. For contract manufacturers, partnering with them for advanced encapsulation solutions can provide a competitive edge. Ingredient suppliers should understand how their products integrate with Lonza's dosage forms to articulate value effectively. Competing directly on core capsule technology is challenging given their scale and IP portfolio, but understanding their innovations is crucial for market relevance.